Our Live Resin carts are as true-to-the-plant experience as you can find in the convenience of a cartridge. We accomplish this by flash-freezing our high-quality flowers immediately after harvest, thus, preserving their unique and distinct terpene profile that would be otherwise lost during weeks of drying and curing. Our oils are then extracted through a hydrocarbon extraction process that separates the High Terpene Extract (HTE) and High Cannabinoid Extract (HCE) products. Once separated, strain-specific HTE is merged with potent THC concentrate distillate at a 30/70 ratio to produce a distinct and unbeatable vaping experience.
Oregon’s Finest Artisanal Cannabis
Distinctively designed, strain-specific live resin cartridges and tinctures
True-to the plant flavor
Looking for a cannabis experience without having to inhale vapor? You’ve come to the right place! Our Full Spectrum Tinctures are made with the same love and care as all of our products and provide a great way to explore your relationship with cannabis. We add high-quality MCT oil to our 30/70 ratio of HTE and high potency THC distillate to formulate a smooth delivery and a true-to-the-plant experience.
You must be 21 years of age or older to find your chalice. Please verify below.
ChromaDex first filed a lawsuit against New York-based Elysium in late 2016 for alleged breach of contract and for not paying for an order of nicotinamide riboside (NR) and pterostilbene, which Elysium uses in its Basis dietary supplement. Over the years, ChromaDex filed additional claims relating to misappropriation of trade secrets, while Elysium counter sued, alleging that ChromaDex overcharged for the ingredients as well as disputing trademark and royalty agreements.
© ftwitty / Getty Images
After a four-day trial, jurors agreed that Elysium had breached the supply agreement for the two ingredients and ordered the company to pay $2,983,350 in damages, plus estimated interest. Total damages from all of the parties’ claims and counterclaims together work out in ChromaDex’s favor, with the California-based company to receive approximately $2.25 to $2.50 million in damages and interest.
“It took nearly five years and has been challenging for both companies, but the jury’s decision finally holds Elysium accountable for paying what it owes,” said ChromaDex CEO Rob Fried. “We now look forward to focusing on the next phase of global growth for Tru Niagen with partners including Sinopharm Xingsha, Nestlé Health Science, Walmart, A.S. Watson Group, H&H Group, W.R. Grace, and Ro.”